adoptive immunotherapy

Summary

Summary: Form of adoptive transfer where cells with antitumor activity are transferred to the tumor-bearing host in order to mediate tumor regression. The lymphoid cells commonly used are lymphokine-activated killer (LAK) cells and tumor-infiltrating lymphocytes (TIL). This is usually considered a form of passive immunotherapy. (From DeVita, et al., Cancer, 1993, pp.305-7, 314)

Top Publications

  1. pmc Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells
    Brian G Till
    Clinical Research Division of the Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Blood 112:2261-71. 2008
  2. pmc Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes
    Mark E Dudley
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20902, USA
    Science 298:850-4. 2002
  3. pmc CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells
    Paul A Antony
    Division of Surgery, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 174:2591-601. 2005
  4. pmc NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo
    Tadepally Lakshmikanth
    Department of Experimental and Clinical Medicine, University of Catanzaro Magna Graecia, Italy
    J Clin Invest 119:1251-63. 2009
  5. pmc Adoptive immunotherapy of cancer using CD4(+) T cells
    Pawel Muranski
    National Cancer Institute, NIH, Bethesda, MD 20892, USA
    Curr Opin Immunol 21:200-8. 2009
  6. ncbi Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy
    Mala Chakraborty
    Laboratory of Tumor Immunology and Biology and Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 170:6338-47. 2003
  7. pmc Increased intensity lymphodepletion and adoptive immunotherapy--how far can we go?
    Pawel Muranski
    Clinical Research Center, National Institutes of Health, Room 3 5762, Bethesda, MD 20892, USA
    Nat Clin Pract Oncol 3:668-81. 2006
  8. pmc Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer
    Rajeev K Shrimali
    Surgery Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892 1201, USA
    Cancer Res 70:6171-80. 2010
  9. pmc Adoptive immunotherapy of prostate cancer bone lesions using redirected effector lymphocytes
    Jehonathan H Pinthus
    Department of Immunology, The Weizmann Institute of Science, Rehovot 76100, Israel
    J Clin Invest 114:1774-81. 2004
  10. ncbi Role of immature myeloid Gr-1+ cells in the development of antitumor immunity
    Qingsheng Li
    Carl C Icahn Institute for Gene Therapy and Molecular Medicine, Mount Sinai School of Medicine, New York, New York, USA
    Cancer Res 64:1130-9. 2004

Research Grants

Detail Information

Publications259 found, 100 shown here

  1. pmc Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells
    Brian G Till
    Clinical Research Division of the Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Blood 112:2261-71. 2008
    b>Adoptive immunotherapy with T cells expressing a tumor-specific chimeric T-cell receptor is a promising approach to cancer therapy that has not previously been explored for the treatment of lymphoma in human subjects...
  2. pmc Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes
    Mark E Dudley
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20902, USA
    Science 298:850-4. 2002
    ..This approach presents new possibilities for the treatment of patients with cancer as well as patients with human immunodeficiency virus-related acquired immunodeficiency syndrome and other infectious diseases...
  3. pmc CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells
    Paul A Antony
    Division of Surgery, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 174:2591-601. 2005
    ..Paradoxically, we found that absence of CD4(+) T cells enhanced adoptive immunotherapy of cancer when using CD8(+) T cells directed against a persisting tumor/self-Ag...
  4. pmc NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo
    Tadepally Lakshmikanth
    Department of Experimental and Clinical Medicine, University of Catanzaro Magna Graecia, Italy
    J Clin Invest 119:1251-63. 2009
    ....
  5. pmc Adoptive immunotherapy of cancer using CD4(+) T cells
    Pawel Muranski
    National Cancer Institute, NIH, Bethesda, MD 20892, USA
    Curr Opin Immunol 21:200-8. 2009
    ....
  6. ncbi Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy
    Mala Chakraborty
    Laboratory of Tumor Immunology and Biology and Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 170:6338-47. 2003
    ..We examined the effect of localized irradiation of s.c. growing tumors on the efficiency of CTL adoptive immunotherapy. Irradiation caused up-regulation of Fas by these tumor cells in situ, based on immunohistochemistry...
  7. pmc Increased intensity lymphodepletion and adoptive immunotherapy--how far can we go?
    Pawel Muranski
    Clinical Research Center, National Institutes of Health, Room 3 5762, Bethesda, MD 20892, USA
    Nat Clin Pract Oncol 3:668-81. 2006
    ..Here we review recent advances in adoptive immunotherapy of solid tumors and discuss the rationale for lymphodepleting conditioning...
  8. pmc Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer
    Rajeev K Shrimali
    Surgery Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892 1201, USA
    Cancer Res 70:6171-80. 2010
    ..These studies provide a rationale for the exploration of combining antiangiogenic agents with ACT for the treatment of patients with cancer...
  9. pmc Adoptive immunotherapy of prostate cancer bone lesions using redirected effector lymphocytes
    Jehonathan H Pinthus
    Department of Immunology, The Weizmann Institute of Science, Rehovot 76100, Israel
    J Clin Invest 114:1774-81. 2004
    ..These preclinical studies strongly support the idea that the T body approach has therapeutic potential in disseminated prostate cancer...
  10. ncbi Role of immature myeloid Gr-1+ cells in the development of antitumor immunity
    Qingsheng Li
    Carl C Icahn Institute for Gene Therapy and Molecular Medicine, Mount Sinai School of Medicine, New York, New York, USA
    Cancer Res 64:1130-9. 2004
    ....
  11. pmc An inducible caspase 9 safety switch for T-cell therapy
    Karin C Straathof
    Center for Cell and Gene Therapy, Baylor College of Meidcine, Houston, TX 77030, USA
    Blood 105:4247-54. 2005
    ..Third, inducible caspase 9 maintains function in T cells overexpressing antiapoptotic molecules. These characteristics favor incorporation of inducible caspase 9 as a safety feature in human T-cell therapies...
  12. doi Cytokine induced killer cells as adoptive immunotherapy strategy to augment graft versus tumor after hematopoietic cell transplantation
    D Sangiolo
    Institute for Cancer Research and Treatment IRCC, Laboratory of Medical Oncology, Strada Provinciale 142, Candiolo TO, Italy
    Expert Opin Biol Ther 9:831-40. 2009
    ..The finding of new cell populations for adoptive immunotherapy, with the ability to separate GVT from GVHD, would be useful...
  13. doi A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma
    Daniel H Palmer
    Cancer Research UK Clinical Trials Unit, CR UK Institute for Cancer Studies, Clinical Research Block
    Hepatology 49:124-32. 2009
    ..Immune responses were assessed using an ELIspot assay of interferon-gamma (IFN-gamma) release. In several cases there was induction of T cell responses to the vaccine and/or AFP following vaccination...
  14. ncbi Engineering hematopoietic grafts: purified allogeneic hematopoietic stem cells plus expanded CD8+ NK-T cells in the treatment of lymphoma
    M R Verneris
    Department of Medicine, Stanford University School of Medicine, California 94305, USA
    Biol Blood Marrow Transplant 7:532-42. 2001
    ..GVT activity is dependent on perforin, but not on Fas-ligand. We conclude that expanded CD8+ NK-T cells may serve as a valuable adjuvant population for allogeneic HCT because they mediate GVT effects with minimal GVHD...
  15. pmc Adoptive immunotherapy against experimental visceral leishmaniasis with CD8+ T cells requires the presence of cognate antigen
    Rosalind Polley
    Immunology and Infection Unit, Dept of Biology, University of York, P O Box 373, York YO10 5YW, United Kingdom
    Infect Immun 74:773-6. 2006
    ..Here, we demonstrate that successful adoptive immunotherapy with CD8+ T cells is strictly dependent upon the presence of cognate antigen.
  16. pmc De novo induction of a cancer/testis antigen by 5-aza-2'-deoxycytidine augments adoptive immunotherapy in a murine tumor model
    Z Sheng Guo
    Thoracic Oncology Section and Tumor Immunology Section, Surgery Branch, National Cancer Institute NIH, Bethesda, MD 20892, USA
    Cancer Res 66:1105-13. 2006
    ..These data show a novel strategy of combined chemoimmunotherapy of cancer targeting a CTA induced de novo in a broad range of tumor histologies, and support further evaluation of chromatin-remodeling agents for human cancer therapy...
  17. pmc Adoptive therapy with redirected primary regulatory T cells results in antigen-specific suppression of arthritis
    Graham P Wright
    Department of Immunology, University College London, Royal Free Hospital, London NW3 2PF, United Kingdom
    Proc Natl Acad Sci U S A 106:19078-83. 2009
    ..This opens the possibility to target Tregs to tissue-specific antigens for the treatment of autoimmune tissue damage without the knowledge of the disease-causing autoantigens recognized by pathogenic T cells...
  18. pmc Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy
    Juhua Zhou
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 175:7046-52. 2005
    Recent studies have indicated that adoptive immunotherapy with autologous antitumor tumor-infiltrating lymphocytes (TILs) following nonmyeloablative chemotherapy mediates tumor regression in approximately 50% of treated patients with ..
  19. ncbi Combination of T-cell therapy and trigger of inflammation induces remodeling of the vasculature and tumor eradication
    Ruth Ganss
    Department of Molecular Immunology, German Cancer Research Center, 69120 Heidelberg, Germany
    Cancer Res 62:1462-70. 2002
    ..Therefore, irradiation/adoptive transfer therapy combines antigen-driven tumor cell eradication with anti-angiogenic effects on tumor endothelium, a powerful synergy that has not been previously appreciated...
  20. ncbi Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma
    Andreas Mackensen
    Department of Hematology Oncology, University of Regensburg, Franz Josef Strauss Allee 11, D 93042 Regensburg, Germany
    J Clin Oncol 24:5060-9. 2006
    ..A phase I study was conducted to test the feasibility, safety, and survival of adoptively transferred Melan-A-specific CTL lines in melanoma patients...
  21. ncbi Minimally invasive treatment combined with cytokine-induced killer cells therapy lower the short-term recurrence rates of hepatocellular carcinomas
    De sheng Weng
    State Key Laboratory of Oncology in Southern China, Biotherapy Center, Department of Imaging and Interventional Radiology, Sun Yat Sen University, Guangzhou, Guangdong, P R China
    J Immunother 31:63-71. 2008
    The recurrence of hepatocellular carcinoma (HCC) after minimally invasive therapy is frequent. Adoptive immunotherapy is thought to be an effective method to lower recurrence and metastasis rates of malignant tumors...
  22. doi Transfer of mRNA encoding recombinant immunoreceptors reprograms CD4+ and CD8+ T cells for use in the adoptive immunotherapy of cancer
    K Birkholz
    Department of Dermatology, University Hospital Erlangen, Erlangen, Germany
    Gene Ther 16:596-604. 2009
    ..with a new defined specificity by expression of a chimeric T-cell receptor (immunoreceptor) for the use in adoptive immunotherapy of cancer...
  23. ncbi Antigen-independent and antigen-dependent methods to numerically expand CD19-specific CD8+ T cells
    Tontanai Numbenjapon
    Division of Molecular Medicine, Beckman Research Institute and City of Hope National Medical Center, Duarte, Calif, USA
    Exp Hematol 35:1083-90. 2007
    ..to express a first-generation CD19-specific chimeric antigen receptor (CAR), designated CD19R, for adoptive immunotherapy of B-lineage leukemias and lymphomas...
  24. ncbi Adoptive immunotherapy of experimental autoimmune encephalomyelitis via T cell delivery of the IL-12 p40 subunit
    G L Costa
    Division of Immunology and Rheumatology, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA
    J Immunol 167:2379-87. 2001
    ..we used the site-specific trafficking properties of autoantigen-reactive CD4+ T cells to develop an adoptive immunotherapy protocol that provided local delivery of a Th1 cytokine antagonist, the p40 subunit of IL-12...
  25. ncbi Effect of selenium on the immunocompetence of patients with head and neck cancer and on adoptive immunotherapy of early and established lesions
    L Kiremidjian-Schumacher
    Division of Biological Sciences, Medicine, and Surgery, New York University College of Dentistry, New York, NY 10010, USA
    Biofactors 14:161-8. 2001
    ..The combined data suggested that local immunotherapy with IL-2 in hosts supplemented with Se may represent an effective modality of treatment for the prevention of recurrences at the site of conventionally treated primary tumors...
  26. ncbi Quantitative assessment of human T lymphocytes in RAG2(-/-)gammac(-/-) mice: the impact of ex vivo manipulation on in vivo functionality
    Rozemarijn S van Rijn
    Jordan Laboratory for Hemato Oncology, Department of Hematology, University Medical Center Utrecht, Utrecht, The Netherlands
    Exp Hematol 35:117-27. 2007
    Recent clinical trials of adoptive immunotherapy showed diminished reactivity of human T cells upon ex vivo manipulation...
  27. ncbi Role of NK cells in adoptive immunotherapy of metastatic colorectal cancer in a syngeneic rat model
    P J Kuppen
    Dept of Surgery, Leiden University Medical Center, The Netherlands
    Immunol Rev 184:236-43. 2001
    ..Our results indicate that NK-cell cancer therapy is still promising and needs improvement...
  28. doi Adoptive immunotherapy using human peripheral blood lymphocytes transferred with RNA encoding Her-2/neu-specific chimeric immune receptor in ovarian cancer xenograft model
    S H Yoon
    Department of Microbiology and Immunology, College of Medicine, Catholic University of Korea, Seoul, Korea
    Cancer Gene Ther 16:489-97. 2009
    ..These results provided evidence that electroporation of CIR RNA to human PBLs could be used for rapid generation and high number of therapeutic antigen-specific T cells for adoptive immunotherapy.
  29. ncbi Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines
    Karl S Peggs
    Royal Free and University College London Medical School, London, UK
    Lancet 362:1375-7. 2003
    ..Our findings indicate that application of CMV-specific cell lines is both feasible and effective in a clinical environment...
  30. ncbi Epstein-Barr virus-specific cytotoxic T-lymphocytes for adoptive immunotherapy of post-transplant lymphoproliferative disease
    David M Burns
    Basic and Clinical Virology Laboratory, Section of Medical Microbiology, University of Edinburgh, R D VS, Summerhall, Edinburgh EH9 1QH, UK
    Blood Rev 18:193-209. 2004
    ..An alternative, adoptive immunotherapy, involving the administration of EBV-specific CTLs cultured in vitro has been developed with the aim of ..
  31. ncbi Generation of B-cell chronic lymphocytic leukemia (B-CLL)-reactive T-cell lines and clones from HLA class I-matched donors using modified B-CLL cells as stimulators: implications for adoptive immunotherapy
    M Hoogendoorn
    Laboratory of Experimental Hematology, Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands
    Leukemia 18:1278-87. 2004
    ..These results show the feasibility of ex vivo generation of B-CLL-reactive CD8(+) CTLs. This opens new perspectives for adoptive immunotherapy, following allogeneic stem cell transplantation in patients with advanced B-CLL.
  32. pmc Persistence of multiple tumor-specific T-cell clones is associated with complete tumor regression in a melanoma patient receiving adoptive cell transfer therapy
    Juhua Zhou
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunother 28:53-62. 2005
    The authors recently reported that adoptive immunotherapy with autologous tumor-reactive tumor infiltrating lymphocytes (TILs) immediately following a conditioning nonmyeloablative chemotherapy regimen resulted in an enhanced clinical ..
  33. ncbi Prognostic significance of adoptive immunotherapy with tumor-associated lymphocytes in patients with advanced gastric cancer: a randomized trial
    Koji Kono
    First Department of Surgery, Yamanashi Medical University, 1110 Tamaho, Yamanashi 409 3898, Japan
    Clin Cancer Res 8:1767-71. 2002
    We performed adoptive immunotherapy (AIT)with tumor-associated lymphocytes (TALs) in combination with chemotherapy in patients with advanced-stage gastric cancer in a randomized controlled study and investigated whether or not an improved ..
  34. pmc Ex vivo expansion of tumor specific lymphocytes with IL-15 and IL-21 for adoptive immunotherapy in melanoma
    Eduardo Huarte
    Department of Medicine, Lebanon, NH 03756, USA
    Cancer Lett 285:80-8. 2009
    ....
  35. pmc Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease
    Catherine M Bollard
    Center for Gene and Cell Therapy, Baylor College of Medicine, 6621 Fannin St, MC 3 3320, Houston, TX 77030, USA
    J Exp Med 200:1623-33. 2004
    ..clearly identified tumor antigens derived from the virus and could, in principle, be a target for adoptive immunotherapy with viral antigen-specific T cells...
  36. doi Adoptive immunotherapy for cancer: the next generation of gene-engineered immune cells
    L J Berry
    Cancer Immunology Program, Peter MacCallum Cancer Centre, Victoria, Australia
    Tissue Antigens 74:277-89. 2009
    ..This review discusses the latest developments in the field of adoptive immunotherapy using genetically modified immune cells that have been transduced with either TCR or scFv receptor ..
  37. ncbi Treatment of advanced gastric cancer by chemotherapy combined with autologous cytokine-induced killer cells
    Jingting Jiang
    The Third Affiliated Hospital, Suzhou University, Changzhou 213003, China
    Anticancer Res 26:2237-42. 2006
    ..It is concluded that chemotherapy plus CIK cells has obvious benefits for patients who suffer from advanced gastric cancers...
  38. ncbi Prospective study of chemotherapy in combination with cytokine-induced killer cells in patients suffering from advanced non-small cell lung cancer
    Changping Wu
    The Third Affiliated Hospital of Suzhou University, Changzhou 213003, PR China
    Anticancer Res 28:3997-4002. 2008
    ..It was concluded that chemotherapy plus CIK cells has potential benefits compared to chemotherapy alone in patients suffering from advanced NSCLC and autologous CIK cell transfusion has no obvious side-effects...
  39. ncbi Adoptive immunotherapy of breast cancer with lymph node cells primed by cryoablation of the primary tumor
    Michael S Sabel
    University of Michigan, Department of Surgery, Division of Surgical Oncology, 3304 Cancer Center, 1500 East Medical Center, Ann Arbor, MI 48109 0932, USA
    Cryobiology 53:360-6. 2006
    ..We examined whether cryoablated tumor draining lymph nodes (CTDLN) as adoptive immunotherapy may be an effective immunotherapeutic approach in the adjuvant treatment of breast cancer...
  40. pmc Adoptive T cell therapy for cancer in the clinic
    Carl H June
    Abramson Family Cancer Research Institute and Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA
    J Clin Invest 117:1466-76. 2007
    ..Improved molecular biology techniques have also increased enthusiasm and feasibility for testing genetically engineered T cells. The current status of the field and prospects for clinical translation are reviewed herein...
  41. pmc The role of regulatory T cells in antigen-induced arthritis: aggravation of arthritis after depletion and amelioration after transfer of CD4+CD25+ T cells
    Oliver Frey
    Institut fur Pathologie, Friedrich Schiller Universitat, Jena, Germany
    Arthritis Res Ther 7:R291-301. 2005
    ..However, transferred Treg cells appear to be unable to counteract established acute or chronic inflammation. This is of considerable importance for the timing of Treg cell transfer in potential therapeutic applications...
  42. doi Graft-versus-leukemia effects of transplantation and donor lymphocytes
    Hans Jochem Kolb
    Department of Medicine 3, Hematopoietic Cell Transplantation, University of Munich and Helmholtz Zentrum Muenchen National Research Centre for Environmental Health, Munich, Germany
    Blood 112:4371-83. 2008
    ..Recently, we have learned from adoptive immunotherapy of viral diseases and HLA-haploidentical stem cell transplantation that T-cell memory may be essential for ..
  43. ncbi Failed adoptive immunotherapy with tumor-specific T cells: reversal with low-dose interleukin 15 but not low-dose interleukin 2
    Sameek Roychowdhury
    Department of Molecular Virology, Immunology, and Medical Genetics, The Ohio State University, Columbus, Ohio 43210, USA
    Cancer Res 64:8062-7. 2004
    b>Adoptive immunotherapy with tumor-specific T cells has emerged as a valid approach for prevention or treatment of diseases, such as melanoma and EBV-associated lymphoma...
  44. ncbi Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: a preclinical study
    John K Chan
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Stanford Cancer Center, Stanford University, Stanford, California, USA
    Clin Cancer Res 12:1859-67. 2006
    ..Bispecific antibodies significantly enhanced the cytotoxicity of CIK cells in primary ovarian cancer cells and in our in vivo mouse model. The mechanism of cytolysis seems to be mediated in part by the NKG2D receptor...
  45. ncbi Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies
    Stephen Gottschalk
    Center for Cell and Gene Therapy, Texas Children s Cancer Center, Departments of Pediatrics, Medicine, and Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX 77030, USA
    Blood 101:1905-12. 2003
    ..Thus, DeltaLMP1 expression in DCs is nontoxic and enables the generation of LMP1-specific CTLs for future adoptive immunotherapy protocols for patients with LMP1-positive malignancies such as EBV-positive Hodgkin disease...
  46. ncbi Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig-coated artificial antigen-presenting cells
    Mathias Oelke
    Department of Pathology and Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland, USA
    Nat Med 9:619-24. 2003
    b>Adoptive immunotherapy holds promise as a treatment for cancer and infectious diseases, but its development has been impeded by the lack of reproducible methods for generating therapeutic numbers of antigen-specific CD8(+) cytotoxic T ..
  47. doi Aurora-A kinase: a novel target of cellular immunotherapy for leukemia
    Toshiki Ochi
    Department of Bioregulatory Medicine, Ehime University Graduate School of Medicine, Toon, Ehime, Japan
    Blood 113:66-74. 2009
    ..Our results indicate that cellular immunotherapy targeting Aur-A is a promising strategy for treatment of leukemia...
  48. pmc Adoptive immunotherapy induces CNS dendritic cell recruitment and antigen presentation during clearance of a persistent viral infection
    Henning Lauterbach
    Molecular and Integrative Neurosciences Department, The Scripps Research Institute, La Jolla, CA 92037, USA
    J Exp Med 203:1963-75. 2006
    ..Administration of exogenously derived pathogen-specific memory T cells (referred to as adoptive immunotherapy) to mice burdened with a persistent lymphocytic choriomeningitis virus (LCMV) infection from birth results ..
  49. ncbi Long-lived antitumor CD8+ lymphocytes for adoptive therapy generated using an artificial antigen-presenting cell
    Marcus O Butler
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Clin Cancer Res 13:1857-67. 2007
    ..To overcome this, we sought to establish a clinical grade culture system that can reproducibly generate antigen-specific cytotoxic T lymphocytes (CTL)...
  50. pmc Differentiation of naive cord-blood T cells into CD19-specific cytolytic effectors for posttransplantation adoptive immunotherapy
    Lisa Marie Serrano
    University of Texas M D Anderson Cancer Center, Pediatrics Research Unit 853, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Blood 107:2643-52. 2006
    ..approach to eliminating residual disease after allogeneic hematopoietic stem cell transplantation, adoptive immunotherapy after UCBT is constrained by the difficulty of generating antigen-specific T cells from functionally naive ..
  51. ncbi Ex vivo culture with interleukin (IL)-12 improves CD8(+) T-cell adoptive immunotherapy for murine leukemia independent of IL-18 or IFN-gamma but requires perforin
    Jennifer N Macgregor
    Department of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, Michigan 48109, USA
    Cancer Res 66:4913-21. 2006
    ..Ex vivo culture with IL-12 may improve CD8(+) T-cell immunotherapy of cancer in the absence of donor cell-derived IFN-gamma via perforin-mediated cytolysis...
  52. doi Clinical-scale generation of human anti-Aspergillus T cells for adoptive immunotherapy
    L Tramsen
    Pediatric Hematology and Oncology, Children s Hospital III, Johann Wolfgang Goethe University, Frankfurt, Germany
    Bone Marrow Transplant 43:13-9. 2009
    ..This method of generating is suitable for future prospective trials designed to evaluate the effect of adoptive immunotherapy in hematopoietic transplant recipients with invasive aspergillosis.
  53. ncbi Expansion of cytotoxic CD3+ CD56+ cells from peripheral blood progenitor cells of patients undergoing autologous hematopoietic cell transplantation
    J C Alvarnas
    Department of Medicine, Stanford University Medical Center, California, USA
    Biol Blood Marrow Transplant 7:216-22. 2001
    ..CIK cells may be expanded from granulocyte colony-stimulating factor-mobilized PBPCs of patients undergoing autologous HCT. CIK cells may provide a potent tool for use in posttransplantation adoptive immunotherapy.
  54. ncbi Generation of cytokine-induced killer cells from leukaemic samples with in vitro cytotoxicity against autologous and allogeneic leukaemic blasts
    Y C Linn
    Department of Haematology, Singapore General Hospital, Singapore
    Br J Haematol 116:78-86. 2002
    ....
  55. doi Reprogramming T lymphocytes for melanoma adoptive immunotherapy by T-cell receptor gene transfer with lentiviral vectors
    Sara Bobisse
    Department of Oncology, University of Padova, Padova, Italy
    Cancer Res 69:9385-94. 2009
    ..Overall, our results indicate that lentiviral vectors represent a valid tool for stable and high-intensity expression of transgenic TCR and support clinical exploitation of this approach for therapeutic application...
  56. ncbi Phase I trial of adoptive immunotherapy with cytolytic T lymphocytes immunized against a tyrosinase epitope
    Malcolm S Mitchell
    Center for Biological Therapy and Melanoma Research, University of California San Diego School of Medicine, San Diego, CA, USA
    J Clin Oncol 20:1075-86. 2002
    ..To study distribution and toxicity of cytolytic T lymphocytes (CTLs) against a single melanoma epitope...
  57. ncbi aPKC inhibitors might be the sensitizer of chemotherapy and adoptive immunotherapy in the treatment of hASIPa-overexpressed breast cancer
    Yi ting Jin
    Department of Surgery, Huashan Hospital, Shanghai Medical School, Fudan University, Shanghai 200040, China
    Oncol Res 17:59-68. 2008
    ..The anticancer effects of 5-FU chemotherapy or adoptive immunotherapy and the synergic action of aPKC inhibitor against hASIPa-overexpressed HBC cells were tested...
  58. ncbi Use of 18F-FDG positron emission tomography following allogeneic transplantation to guide adoptive immunotherapy with donor lymphocyte infusions
    D P Hart
    Department of Haematology, University College London Hospital, London, UK
    Br J Haematol 128:824-9. 2005
    ..This retrospective pilot study forms the basis for a prospective study to clarify the utility of (18)F-FDG PET/CT in these patients...
  59. ncbi Manufacturing of large numbers of patient-specific T cells for adoptive immunotherapy: an approach to improving product safety, composition, and production capacity
    Chy Anh Tran
    Division of Hematology Hematopoietic Cell Transplantation, City of Hope National Medical Center and Beckman Research Institute, Duarte, CA 91010, USA
    J Immunother 30:644-54. 2007
    ..of patient-specific cell products to produce large numbers of T-lymphocytes in support of phase 2 adoptive immunotherapy trials for hematologic malignancies...
  60. ncbi Exhaustion of cytotoxic T cells during adoptive immunotherapy of virus carrier mice can be prevented by B cells or CD4+ T cells
    Lukas Hunziker
    Institute of Experimental Immunology, Department of Pathology, University of Zurich, Zurich, Switzerland
    Eur J Immunol 32:374-82. 2002
    ..of antiviral CTL after transfusion into persistently infected individuals is a serious limitation of adoptive immunotherapy protocols...
  61. ncbi Fiber-modified adenoviruses generate subgroup cross-reactive, adenovirus-specific cytotoxic T lymphocytes for therapeutic applications
    Ann M Leen
    Center for Cell and Gene Therapy, Department of Pediatrics, 6621 Fannin S, MC 3 3320, Houston, TX 77030, USA
    Blood 103:1011-9. 2004
    ..To date there is no therapy. The present study was motivated by the potential for using adoptive immunotherapy as either prophylaxis or treatment for Ad infections and associated diseases...
  62. ncbi Adoptive immunotherapy for pancreatic cancer using MUC1 peptide-pulsed dendritic cells and activated T lymphocytes
    Hiroshi Kondo
    Department of Digestive Surgery and Surgical Oncology, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi 755 8505, Japan
    Anticancer Res 28:379-87. 2008
    ..The clinical efficacy of immunotherapy using both dendritic cells pulsed with MUC1 peptide (MUC1-DC) and, cytotoxic T lymphocyte (CTL) sensitized with a pancreatic cancer, YPK-1, expressing MUC1 (MUC1-CTL) was evaluated...
  63. ncbi Adoptive immunotherapy with antigen-specific T cells in myeloma: a model of tumor-specific donor lymphocyte infusion
    Larry W Kwak
    Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892, USA
    Semin Oncol 31:37-46. 2004
    ..Donor immunization with myeloma idiotype protein in the setting of a nonmyeloablative SCT may represent a novel strategy for the treatment of myeloma...
  64. ncbi Adoptive immunotherapy to increase the level of donor hematopoietic chimerism after nonmyeloablative marrow transplantation for severe canine hereditary hemolytic anemia
    Alessandra Takatu
    Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    Biol Blood Marrow Transplant 9:674-82. 2003
    ..We conclude that DLI after nonmyeloablative HCT can increase the levels of donor cells contributing to hematopoiesis in recipients, inducing remissions of the hemolytic process and preventing complications associated with iron overload...
  65. pmc Adoptive immunotherapy mediated by ex vivo expanded natural killer T cells against CD1d-expressing lymphoid neoplasms
    Davide Bagnara
    Human Anatomy Section, Department of Experimental Medicine, University of Genoa, Genoa, Italy
    Haematologica 94:967-74. 2009
    ..Alpha-galactosylceramide (alpha-GalCer) is a glycolipid that can be presented to cytotoxic CD1d-restricted T cells. These reagents represent a potentially powerful tool for cell mediated immunotherapy...
  66. doi Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial
    S Arai
    Rush University Medical Center, Chicago, Illinois, USA
    Cytotherapy 10:625-32. 2008
    ....
  67. ncbi Schizophrenia and other mental disorders require long-term adoptive immunotherapy
    Rudolf Wank
    Institute of Immunology, Klinikum Innenstadt, University of Munich, Goethestrasse 31, 80336 Munich, Germany
    Med Hypotheses 59:154-8. 2002
    ..R. Lewis, S.J. Wiegand, R.M. Lindsay, Pharmacol. Biochem. Be 56 (1997) 131-137]. The hypothesis that adoptive immunotherapy is effective in psychiatric disorders will be supported by three case reports, in a patient with bipolar ..
  68. ncbi Adoptive immunotherapy in canine mixed chimeras after nonmyeloablative hematopoietic cell transplantation
    G E Georges
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Department of Medicine, University of Washington, Seattle, WA 98109 1024, USA
    Blood 95:3262-9. 2000
    ..In the current study, we examined whether donor lymphocyte infusion (DLI) could be used as adoptive immunotherapy to convert mixed to complete donor chimerism...
  69. ncbi Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine
    J Banchereau
    Baylor Institute for Immunology Research, Dallas, Texas 75204, USA
    Cancer Res 61:6451-8. 2001
    ..Regression of >1 tumor metastases were observed in seven of these patients. The overall immunity to MelAgs after DC vaccination is associated with clinical outcome (P = 0.015)...
  70. ncbi Host lymphodepletion augments T cell adoptive immunotherapy through enhanced intratumoral proliferation of effector cells
    Li Xin Wang
    Center for Surgery Research, Division of Surgery, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Cancer Res 65:9547-54. 2005
    T-cell adoptive immunotherapy for stringent murine tumor models, such as intracranial, s.c., or advanced pulmonary metastases, routinely uses lymphodepletive conditioning regimens before T-cell transfer, like recent clinical protocols...
  71. ncbi Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases
    S Sakaguchi
    Precursory Research for Embryonic Science and Technology PRESTO, Research and Development Corporation of Japan JRDC, Tsukuba Life Science Center
    J Immunol 155:1151-64. 1995
    ..Abnormality of this T cell-mediated mechanism of peripheral tolerance can be a possible cause of various autoimmune diseases...
  72. ncbi Generation of autologous Epstein-Barr virus-specific cytotoxic T cells for adoptive immunotherapy in solid organ transplant recipients
    B Savoldo
    Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX 77030, USA
    Transplantation 72:1078-86. 2001
    ..b>Adoptive immunotherapy may have therapeutic potential in this setting, but there is little experience in generating autologous ..
  73. ncbi Adoptive immunotherapy of HCMV infection
    M Kapp
    Medizinische Klinik und Poliklinik II, Julius Maximilians University of Wurzburg, Germany
    Cytotherapy 9:699-711. 2007
    ..In this review, we aim to provide a comprehensive synopsis of the current standard of knowledge concerning cellular HCMV-specific immunotherapeutic approaches...
  74. ncbi CD34+-derived CD11c+ + + BDCA-1+ + CD123+ + DC: expansion of a phenotypically undescribed myeloid DC1 population for use in adoptive immunotherapy
    K A Ward
    Bone Marrow Transplant Programme, Alfred Hospital, Melbourne, Australia
    Cytotherapy 8:130-40. 2006
    ..However, significant heterogeneity within DC preparations is apparent and supports the existence of several distinct DC subpopulations. This study aimed to expand and characterize CD34+ DC for use in immunotherapy...
  75. ncbi Rapid enrichment of human papillomavirus (HPV)-specific polyclonal T cell populations for adoptive immunotherapy of cervical cancer
    Annemieke de Jong
    Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Building 1 E3 Q, 2300 RC Leiden, The Netherlands
    Int J Cancer 114:274-82. 2005
    ..These HPV16E6-specific CD4(+) T cells may turn out to be an essential component of future adoptive T cell therapy for advanced cervical cancer, by orchestrating CTL dependent and independent tumoricidal mechanisms...
  76. ncbi Safety profile and anti-tumor effects of adoptive immunotherapy using gamma-delta T cells against advanced renal cell carcinoma: a pilot study
    Hirohito Kobayashi
    Department of Urology, Tokyo Women s Medical University, 8 1 Kawada cho, Shinjuku ku, Tokyo 162 8666, Japan
    Cancer Immunol Immunother 56:469-76. 2007
    ..have been used to improve the prognosis of patients with advanced renal cell carcinoma (RCC), adoptive immunotherapy using gamma-delta (gammadelta) T cells has not yet been tried...
  77. ncbi Adoptive immunotherapy for pancreatic cancer: cytotoxic T lymphocytes stimulated by the MUC1-expressing human pancreatic cancer cell line YPK-1
    Toru Kawaoka
    Department of Digestive Surgery and Surgical Oncology Department of Surgery II, Yamaguchi University Graduate School of Medicine, Yamaguchi 755 8505, Japan
    Oncol Rep 20:155-63. 2008
    ..In this study, we performed adoptive immunotherapy (AIT) in patients with PC with CTLs stimulated by the MUC1-expressing human PC cell line YPK-1...
  78. ncbi Revealing lymphoma growth and the efficacy of immune cell therapies using in vivo bioluminescence imaging
    Matthias Edinger
    Division of Bone Marrow Transplantation, Department of Medicine, Stanford University School of Medicine, CA, USA
    Blood 101:640-8. 2003
    ..The complex cellular processes in bone marrow transplantation and antitumor immunotherapy, previously inaccessible to investigation, can now be revealed in real time in living animals...
  79. ncbi Photodynamic purging of alloreactive T cells for adoptive immunotherapy after haploidentical stem cell transplantation
    Katia Perruccio
    Department of Clinical and Experimental Medicine, IRCCS Foundation on Transplantation Biotechnologies, University of Perugia, Via Brunamonti 51, 06123, Italy
    Blood Cells Mol Dis 40:76-83. 2008
    ..Consequently, a clinical trial is planned to incorporate infusion of photo-allodepleted donor T cells after haploidentical stem cell transplantation with the aim of decreasing infection-related mortality...
  80. ncbi In vitro methods for generating CD8+ T-cell clones for immunotherapy from the naïve repertoire
    William Y Ho
    Program in Immunology, Fred Hutchinson Cancer Research Center and the Department of Medicine, University of Washington, Seattle, WA 98109, USA
    J Immunol Methods 310:40-52. 2006
    ..on in vivo vaccination trials, but also to generate T-cell lines or clones that could be used directly for adoptive immunotherapy approaches...
  81. ncbi Adoptive immunotherapy of cancer using ex vivo expanded human gammadelta T cells: A new approach
    Pouneh Dokouhaki
    Toronto General Research Institute, University Health Network, Toronto, Canada
    Cancer Lett 297:126-36. 2010
    gammadelta T cells can be an option for adoptive immunotherapy of cancer. The major obstacle to clinical application of gammadelta T cells is their low number and lack of a reliable method to expand them consistently and efficiently...
  82. doi Optimization of LMP-specific CTL expansion for potential adoptive immunotherapy in NPC patients
    Viviana P Lutzky
    EBV Biology Laboratory, Division of Immunology, Australian Centre for Vaccine Development, The Queensland Institute of Medical Research, The Royal Brisbane Hospital, 300 Herston Road, Herston, Brisbane, QLD 4006, Australia
    Immunol Cell Biol 87:481-8. 2009
    ..In order to maximize the expansion of LMP-specific CTL in vitro for use in adoptive immunotherapy of nasopharyngeal carcinoma patients, we used lymphoblastoid cell lines coated with synthetic peptides ..
  83. ncbi Next generation adoptive immunotherapy--human T cells as carriers of therapeutic nanoparticles
    M W Mortensen
    Nano Science Center, University of Copenhagen, Universitetsparken 5, DK 2100 Copenhagen, Denmark
    J Nanosci Nanotechnol 7:4575-80. 2007
    An important step in adoptive immunotherapy in general and specifically with respect to cancer treatment is the initiation of an inflammatory T cell response at the tumor site...
  84. pmc Acute myeloid leukaemia cells secrete a soluble factor that inhibits T and NK cell proliferation but not cytolytic function--implications for the adoptive immunotherapy of leukaemia
    J K Orleans-Lindsay
    Department of Haematology, Royal Free University College Medical School, London, UK
    Clin Exp Immunol 126:403-11. 2001
    Evidence of an immune mediated graft-versus-leukaemia effect has led to the belief that T and NK cell based adoptive immunotherapy can constitute effective treatment for relapsed leukaemias...
  85. pmc Pilot study of sentinel-node-based adoptive immunotherapy in advanced colorectal cancer
    Mona Karlsson
    Karolinska Institute, Department of Medicine, Karolinska University Hospital, Stockholm, Sweden
    Ann Surg Oncol 17:1747-57. 2010
    ..We have conducted a pilot study of a novel adoptive immunotherapy, using autologous, in vitro expanded lymphocytes isolated from the tumor-draining sentinel lymph node.
  86. ncbi Resistance of cancers to immunologic cytotoxicity and adoptive immunotherapy via X-linked inhibitor of apoptosis protein expression and coexisting defects in mitochondrial death signaling
    Rajani Ravi
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Johns Hopkins University School of Medicine, 1650 Orleans Street, Baltimore, MD 21231, USA
    Cancer Res 66:1730-9. 2006
    ....
  87. ncbi Treatment of nasopharyngeal carcinoma with Epstein-Barr virus--specific T lymphocytes
    Karin C M Straathof
    Center for Cell and Gene Therapy, Department of Pediatrics, Baylor College of Medicine, 1102 Bates St, Suite 1120, Houston, TX 77030, USA
    Blood 105:1898-904. 2005
    ..These results demonstrate that administration of EBV-specific CTLs to patients with advanced NPC is feasible, appears to be safe, and can be associated with significant antitumor activity...
  88. ncbi Natural-killer-cell-based treatment in haematopoietic stem-cell transplantation
    Jakob R Passweg
    Service d Hematologie, Departement Medecine Interne, Hopitaux Universitaires de Geneve, Geneve, Switzerland
    Best Pract Res Clin Haematol 19:811-24. 2006
    b>Adoptive immunotherapy using natural killer (NK) cells is currently under investigation, especially in situations where anti-neoplastic effect is needed but infusion of T cells is considered hazardous, such as in recipients of ..
  89. pmc CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy
    J L Schultze
    Department of Adult Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    J Clin Invest 100:2757-65. 1997
    ..We, therefore, contend that CD40-activated B cells are an alternative source of highly efficient APCs with which to generate antigen-specific T cells ex vivo for autologous adoptive immunotherapy.
  90. pmc A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma
    Mark E Dudley
    Surgery Branch, National Cancer Institute, Building 10, Room 2B08, 9000 Rockville Pike, Bethesda, MD 20892, USA
    J Immunother 25:243-51. 2002
    ..a phase I clinical trial using nonmyeloablative, lympho-depleting chemotherapy in combination with adoptive immunotherapy in patients with metastatic melanoma...
  91. ncbi Immune and clinical outcomes in patients with stage IV melanoma vaccinated with peptide-pulsed dendritic cells derived from CD34+ progenitors and activated with type I interferon
    Jacques Banchereau
    Baylor Institute for Immunology Research, Dallas, TX, USA
    J Immunother 28:505-16. 2005
    ..Overall, these results suggest that IFN-alpha-activated CD34-DCs are safe but elicit only limited immune responses, underscoring the need to test different DC maturation factors...
  92. ncbi Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma
    M E Dudley
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 1502, USA
    J Immunother 24:363-73. 2001
    ..The lack of clinical effectiveness of this protocol suggests that transfer of different or additional cell types or that modulation of the recipient host environment is required for successful therapy...
  93. ncbi CD4+CD25+ T regulatory cells suppress NK cell-mediated immunotherapy of cancer
    Mark J Smyth
    Cancer Immunology Program, Trescowthick Laboratories, Peter MacCallum Cancer Centre, East Melbourne, Australia
    J Immunol 176:1582-7. 2006
    ..Our data illustrate at least one mechanism by which Treg can suppress NK cell antitumor activity and highlight the effectiveness of combining Treg inhibition with subsequent NK cell activation to promote strong innate antitumor immunity...
  94. ncbi A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma
    Thomas Leemhuis
    Division of Bone Marrow Transplantation, Stanford University Medical Center, California, USA
    Biol Blood Marrow Transplant 11:181-7. 2005
    ....
  95. ncbi Human minor histocompatibility antigens: new concepts for marrow transplantation and adoptive immunotherapy
    E Goulmy
    Department of Immunohematology and Blood Bank, Leiden University Hospital, The Netherlands
    Immunol Rev 157:125-40. 1997
    ..Directly relevant is the utility of mHag molecular typing for diagnostics in BM donor selection. Most promising is the use of mHag-specific cytotoxic T cells for adoptive immunotherapy of leukemia.
  96. ncbi Silencing of SOCS1 enhances antigen presentation by dendritic cells and antigen-specific anti-tumor immunity
    Lei Shen
    Center for Cell and Gene Therapy, Baylor College of Medicine, One Baylor Plaza, Houston, Texas 77030, USA
    Nat Biotechnol 22:1546-53. 2004
    ..This study has implications for understanding the regulation of antigen presentation and for developing more effective tumor vaccines by silencing the critical brake in antigen presentation...
  97. ncbi Low-dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma
    Nicolaus Kroger
    Department of Bone Marrow Transplantation, University Hospital Hamburg Eppendorf, Martinistrasse 52, D 20246 Hamburg, Germany
    Blood 104:3361-3. 2004
    ..The 2-year estimated overall and progression-free survival were 100% and 84%, respectively. Adoptive immunotherapy with low-dose thalidomide and DLI induces a strong antimyeloma effect with low incidence of graft versus ..
  98. pmc Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity
    Christian S Hinrichs
    National Cancer Institute, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 106:17469-74. 2009
    ..better than those derived from effector memory populations, suggesting that they are superior for use in adoptive immunotherapy studies...
  99. ncbi Ex vivo expansion of highly purified NK cells for immunotherapy after haploidentical stem cell transplantation in children
    U Koehl
    University Hospital Frankfurt, Pediatric Hematology and Oncology, Frankfurt, Germany
    Klin Padiatr 217:345-50. 2005
    ..For a possible benefit of post transplant treatment with NK cells after haploidentical stem cell transplantation (haplo-SCT) we developed a clinical scale procedure for NK cell processing observing Good Manufacturing Practice (GMP)...
  100. ncbi Polarization effects of 4-1BB during CD28 costimulation in generating tumor-reactive T cells for cancer immunotherapy
    Qiao Li
    Division of Surgical Oncology, University of Michigan, Comprehensive Cancer Center, Ann Arbor, Michigan 48109 0932, USA
    Cancer Res 63:2546-52. 2003
    ..of TDLN cells activated through 4-1BB in conjunction with CD3/CD28 pathways was examined using an adoptive immunotherapy model...
  101. ncbi The role of the combination of IL-2 and TGF-beta or IL-10 in the generation and function of CD4+ CD25+ and CD8+ regulatory T cell subsets
    David A Horwitz
    Division of Rheumatology and Immunology, Department of Medicine, Keck School of Medicine of the University of Southern California, Los Angeles 90033 1034, USA
    J Leukoc Biol 74:471-8. 2003
    ..Finally, the potential use of regulatory T cells generated ex vivo as an adoptive immunotherapy for certain autoimmune diseases, to prevent organ graft rejection, or to prevent pathologic host responses ..

Research Grants82

  1. Personalized Clinical Diagnostics and Beyond: Integrated Ring Resonator Arrays
    Ryan Bailey; Fiscal Year: 2009
    ..This technology promises to broadly impact the landscape of the biomedical sciences, both meeting the clinical diagnostic challenges of today and pioneering the paradigm-shifting discoveries of tomorrow. ..
  2. Transplant Tolerance in Non-Human Primates
    Christian Larsen; Fiscal Year: 2007
    ..and tolerance, and 3) the effect that depletion of recipient natural killer cells, or delivery of adoptive immunotherapy with either regulatory or conventional T cells will have on chimerism, survival of renal allografts, the ..
  3. Transplant Tolerance in Non-Human Primates
    Christian Larsen; Fiscal Year: 2009
    ..and tolerance, and 3) the effect that depletion of recipient natural killer cells, or delivery of adoptive immunotherapy with either regulatory or conventional T cells will have on chimerism, survival of renal allografts, the ..
  4. Transplant Tolerance in Non-Human Primates
    Christian Larsen; Fiscal Year: 2009
    ..and tolerance, and 3) the effect that depletion of recipient natural killer cells, or delivery of adoptive immunotherapy with either regulatory or conventional T cells will have on chimerism, survival of renal allografts, the ..
  5. Targeting MCPyV to Overcome Immune Evasion in Merkel Cell Carcinoma
    Paul Nghiem; Fiscal Year: 2010
    ..the immune evasion strategies adopted by MCC and begin the process of developing rational vaccine or adoptive immunotherapy for this disease...
  6. Targeting MCPyV to Overcome Immune Evasion in Merkel Cell Carcinoma
    Paul Nghiem; Fiscal Year: 2009
    ..the immune evasion strategies adopted by MCC and begin the process of developing rational vaccine or adoptive immunotherapy for this disease...
  7. CD8+ T Cell Immunity to Cytomegalovirus
    Stanley Riddell; Fiscal Year: 2009
    ..by this project have investigated the immunobiology of CMV infection and developed strategies for specific adoptive immunotherapy with CD8+ T cell clones to correct deficiencies of T cell immunity that permit the progression of CMV ..
  8. CD8+ T Cell Immunity to Cytomegalovirus
    Stanley R Riddell; Fiscal Year: 2010
    ..by this project have investigated the immunobiology of CMV infection and developed strategies for specific adoptive immunotherapy with CD8+ T cell clones to correct deficiencies of T cell immunity that permit the progression of CMV ..
  9. RENAL CELL CARCINOMA--ADOPTIVE IMMUNOTHERAPY
    KURT STENZEL; Fiscal Year: 1990
    ..Methodology and feasibility for on-line activation of lymphoid cells for adoptive immunotherapy will be investigated using a murine tumor model.
  10. Imaging Infused CD19 Specific T Cells in the Tumor
    LAURENCE COOPER; Fiscal Year: 2007
    ..Gene therapy can improve the therapeutic potential of adoptive immunotherapy and as recently published (Science 2006 Aug 31), infusion of genetically modified T cells with redirected ..
  11. CELLULAR IMMUNOTHERAPY FOR HEMATOLOGIC MALIGNANCY
    John Levine; Fiscal Year: 2001
    ..The candidate proposes a strategy of a low intensity conditioned transplant followed by prophylactic adoptive immunotherapy as a means of preventing relapse through GVL while minimizing risk of GVHD or regimen-related toxicity. Dr...
  12. CELLULAR IMMUNOTHERAPY FOR HEMATOLOGIC MALIGNANCY
    John Levine; Fiscal Year: 2003
    ..The candidate proposes a strategy of a low intensity conditioned transplant followed by prophylactic adoptive immunotherapy as a means of preventing relapse through GVL while minimizing risk of GVHD or regimen-related toxicity. Dr...
  13. CELLULAR IMMUNOTHERAPY FOR HEMATOLOGIC MALIGNANCY
    John Levine; Fiscal Year: 2002
    ..The candidate proposes a strategy of a low intensity conditioned transplant followed by prophylactic adoptive immunotherapy as a means of preventing relapse through GVL while minimizing risk of GVHD or regimen-related toxicity. Dr...
  14. CELLULAR IMMUNOTHERAPY FOR HEMATOLOGIC MALIGNANCY
    John Levine; Fiscal Year: 2006
    ..The candidate proposes a strategy of a low intensity conditioned transplant followed by prophylactic adoptive immunotherapy as a means of preventing relapse through GVL while minimizing risk of GVHD or regimen-related toxicity. Dr...
  15. CELLULAR IMMUNOTHERAPY FOR HEMATOLOGIC MALIGNANCY
    John Levine; Fiscal Year: 2005
    ..The candidate proposes a strategy of a low intensity conditioned transplant followed by prophylactic adoptive immunotherapy as a means of preventing relapse through GVL while minimizing risk of GVHD or regimen-related toxicity. Dr...
  16. CELLULAR IMMUNOTHERAPY FOR HEMATOLOGIC MALIGNANCY
    John Levine; Fiscal Year: 2004
    ..The candidate proposes a strategy of a low intensity conditioned transplant followed by prophylactic adoptive immunotherapy as a means of preventing relapse through GVL while minimizing risk of GVHD or regimen-related toxicity. Dr...
  17. Adoptive Transfer of AlloCTL for Immunotherapy of Recurrent Gliomas
    Linda M Liau; Fiscal Year: 2012
    ..Toward these goals, we have actively explored permutations of local adoptive immunotherapy for human malignant gliomas with autologous and allogeneic effector cells...
  18. Adoptive Transfer of AlloCTL for Immunotherapy of Recurrent Gliomas
    Linda M Liau; Fiscal Year: 2010
    ..Toward these goals, we have actively explored permutations of local adoptive immunotherapy for human malignant gliomas with autologous and allogeneic effector cells...
  19. Leukocyte-Endothelial Adhesion in Tumor Immunity
    Sharon Evans; Fiscal Year: 2009
    ..molecules (adhesion receptors, chemokines) that recruit T cells in a murine B16 melanoma model of adoptive immunotherapy. Complementary in situ imaging studies will investigate the contribution of endogenous human IL-6 in ..
  20. Leukocyte-Endothelial Adhesion in Tumor Immunity
    Sharon S Evans; Fiscal Year: 2010
    ..molecules (adhesion receptors, chemokines) that recruit T cells in a murine B16 melanoma model of adoptive immunotherapy. Complementary in situ imaging studies will investigate the contribution of endogenous human IL-6 in ..
  21. SPORE in Lymphoma
    Richard Ambinder; Fiscal Year: 2006
    ..decisions regarding the duration or intensity of therapy and to determine whether vaccination and/or adoptive immunotherapy strategies may ultimately allow standard therapies to be shortened or de-escalated in some patients...
  22. SPORE in Lymphoma
    Richard Ambinder; Fiscal Year: 2007
    ..decisions regarding the duration or intensity of therapy and to determine whether vaccination and/or adoptive immunotherapy strategies may ultimately allow standard therapies to be shortened or de-escalated in some patients...
  23. SPORE in Lymphoma
    Richard Ambinder; Fiscal Year: 2003
    ..decisions regarding the duration or intensity of therapy and to determine whether vaccination and/or adoptive immunotherapy strategies may ultimately allow standard therapies to be shortened or de-escalated in some patients...
  24. SPORE in Lymphoma
    Richard Ambinder; Fiscal Year: 2004
    ..decisions regarding the duration or intensity of therapy and to determine whether vaccination and/or adoptive immunotherapy strategies may ultimately allow standard therapies to be shortened or de-escalated in some patients...
  25. SPORE in Lymphoma
    Richard Ambinder; Fiscal Year: 2005
    ..decisions regarding the duration or intensity of therapy and to determine whether vaccination and/or adoptive immunotherapy strategies may ultimately allow standard therapies to be shortened or de-escalated in some patients...
  26. SPORE in Lymphoma
    Richard Ambinder; Fiscal Year: 2002
    ..decisions regarding the duration or intensity of therapy and to determine whether vaccination and/or adoptive immunotherapy strategies may ultimately allow standard therapies to be shortened or de-escalated in some patients...
  27. SPORE in Lymphoma
    Richard Ambinder; Fiscal Year: 2009
    ..decisions regarding the duration or intensity of therapy and to determine whether vaccination and/or adoptive immunotherapy strategies may ultimately allow standard therapies to be shortened or de-escalated in some patients...
  28. EBV and Hodgkins disease
    Richard Ambinder; Fiscal Year: 2002
    ..decisions regarding the duration or intensity of therapy and to determine whether vaccination and/or adoptive immunotherapy strategies may ultimately allow standard therapies to be shortened or de-escalated in some patients...
  29. NOVEL SUICIDE GENE FOR THERAPY OF GRAFT VS HOST DISEASE
    Stanley Riddell; Fiscal Year: 2000
    ..stem cell transplant recipients who receive donor T lymphocytes modified to express NGFR-2FKBP-Fas as adoptive immunotherapy for relapsed chronic myeloid leukemia...
  30. NATURAL AND PREDICTED ANTIGENS FOR TB IMMUNOTHERAPY
    Anne De Groot; Fiscal Year: 1993
    ..I will also explore the potential use of "protective" antigens in the development of an adoptive immunotherapy technique for the treatment of multi-drug resistant TB...
  31. T CELL BASED IMMUNOTHERAPY IN A MELANOMA CULTURE SYSTEM
    Dorothee Herlyn; Fiscal Year: 2001
    ..Identification of these factors will reveal new ways to make effective adoptive immunotherapy of cancer patients...
  32. T CELL TRAFFICKING IN ADOPTIVE CELLULAR IMMUNOTHERAPY
    Lloyd Stoolman; Fiscal Year: 1999
    ..Finally, the collaboration between the PI and co-PI will enhance productivity and ensure the rapid transfer of information from a pre-clinical to a clinical setting. ..
  33. T CELL TRAFFICKING IN ADOPTIVE CELLULAR IMMUNOTHERAPY
    Lloyd Stoolman; Fiscal Year: 2000
    ..Finally, the collaboration between the PI and co-PI will enhance productivity and ensure the rapid transfer of information from a pre-clinical to a clinical setting. ..
  34. DEVELOPING T CELLS CLONES CYTOTOXIC TO SARCOMAS
    Michael Mastrangelo; Fiscal Year: 1990
    ..The ultimate goal of this proposal is development of a more effective, safer, specific adoptive immunotherapy regimen for sarcoma patients through improved understanding of the immunobiology of the disease and of the ..
  35. IMMUNOTHERAPY OF MELANOMA WITH ACTIVATED LYMPHOCYTES
    STANLEY LEONG; Fiscal Year: 1999
    ..and to activate and expand these pre-effector cells in vitro to become anti-tumor effector cells for adoptive immunotherapy. The specific aims are: (1) to study the immune response of patients undergoing T cell immunotherapy; (2) ..
  36. IMMUNOTHERAPY OF MELANOMA WITH ACTIVATED LYMPHOCYTES
    STANLEY LEONG; Fiscal Year: 2000
    ..and to activate and expand these pre-effector cells in vitro to become anti-tumor effector cells for adoptive immunotherapy. The specific aims are: (1) to study the immune response of patients undergoing T cell immunotherapy; (2) ..
  37. Novel Biologic Therapies for BMT: Mechanistic Evaluation in Rhesus Macaques
    Leslie S Kean; Fiscal Year: 2010
    ..1) most novel therapies for BMT (including T cell costimulation blockade, T cell adhesion blockade and adoptive immunotherapy with regulatory T cells) cannot be accurately tested in either murine or canine models for aGvHD and (2) ..
  38. IMMUNE RESPONSE TO GENE MODIFIED TUMOR
    Bernard Fox; Fiscal Year: 1999
    ..cytokine response is critical to the generation of critical to the generation of therapeutic T cells for adoptive immunotherapy. To test these hypothesis, it is essential that the immune response of patients to vaccination by ..
  39. CTLA-4 Blockade in Allo Stem Cell Transplantation
    Asad Bashey; Fiscal Year: 2003
    ..There exists considerable evidence that adoptive immunotherapy in the form of a donor T-cell mediated graft-versus-malignancy (GVM) is an important component of the ..
  40. CTLA-4 Blockade in Allo Stem Cell Transplantation
    Edward Ball; Fiscal Year: 2005
    ..There exists considerable evidence that adoptive immunotherapy in the form of a donor T-cell mediated graft-versus-malignancy (GVM) is an important component of the ..
  41. CTLA-4 Blockade in Allo Stem Cell Transplantation
    Asad Bashey; Fiscal Year: 2002
    ..There exists considerable evidence that adoptive immunotherapy in the form of a donor T-cell mediated graft-versus-malignancy (GVM) is an important component of the ..
  42. P1 - COMBINATION ACTIVATED T-CELL AND VACCINE THERAPY IN MYELOMA
    Larry W Kwak; Fiscal Year: 2011
    ..the vaccine studies, our recent randomized phase l/ll studies in subjects with advanced myeloma showed adoptive immunotherapy with vaccine primed T cells resulted in an encouraging immunologic reconstitution following high dose ..
  43. CTLA-4 Blockade in Allo Stem Cell Transplantation
    Asad Bashey; Fiscal Year: 2004
    ..There exists considerable evidence that adoptive immunotherapy in the form of a donor T-cell mediated graft-versus-malignancy (GVM) is an important component of the ..
  44. CHRONIC LYMPHOCYTIC LEUKEMIA RESEARCH CONSORTIUM
    Thomas Kipps; Fiscal Year: 2005
    ..Project 4 (Gribben PI) examines T cell anergy, stem cell transplantation, and the potential for adoptive immunotherapy of CLL using autologous or allogeneic leukemia-transplantation, and the potential for adoptive ..
  45. CHRONIC LYMPHOCYTIC LEUKEMIA RESEARCH CONSORTIUM
    Thomas Kipps; Fiscal Year: 2000
    ..Project 4 (Gribben PI) examines T cell anergy, stem cell transplantation, and the potential for adoptive immunotherapy of CLL using autologous or allogeneic leukemia-transplantation, and the potential for adoptive ..
  46. CHRONIC LYMPHOCYTIC LEUKEMIA RESEARCH CONSORTIUM
    Thomas Kipps; Fiscal Year: 2004
    ..Project 4 (Gribben PI) examines T cell anergy, stem cell transplantation, and the potential for adoptive immunotherapy of CLL using autologous or allogeneic leukemia-transplantation, and the potential for adoptive ..
  47. CHRONIC LYMPHOCYTIC LEUKEMIA RESEARCH CONSORTIUM
    Thomas Kipps; Fiscal Year: 2002
    ..Project 4 (Gribben PI) examines T cell anergy, stem cell transplantation, and the potential for adoptive immunotherapy of CLL using autologous or allogeneic leukemia-transplantation, and the potential for adoptive ..
  48. CHRONIC LYMPHOCYTIC LEUKEMIA RESEARCH CONSORTIUM
    Thomas Kipps; Fiscal Year: 2001
    ..Project 4 (Gribben PI) examines T cell anergy, stem cell transplantation, and the potential for adoptive immunotherapy of CLL using autologous or allogeneic leukemia-transplantation, and the potential for adoptive ..
  49. CHRONIC LYMPHOCYTIC LEUKEMIA RESEARCH CONSORTIUM
    Thomas Kipps; Fiscal Year: 2003
    ..Project 4 (Gribben PI) examines T cell anergy, stem cell transplantation, and the potential for adoptive immunotherapy of CLL using autologous or allogeneic leukemia-transplantation, and the potential for adoptive ..
  50. CHRONIC LYMPHOCYTIC LEUKEMIA RESEARCH CONSORTIUM
    Thomas Kipps; Fiscal Year: 2001
    ..Project 4 (Gribben PI) examines T cell anergy, stem cell transplantation, and the potential for adoptive immunotherapy of CLL using autologous or allogeneic leukemia-transplantation, and the potential for adoptive ..
  51. Host-tumor cell interaction in myeloma: therapeutic applications
    Kenneth C Anderson; Fiscal Year: 2010
    ..Cell-Host Bone Marrow Interactions 8 PROJECT 2: Innate and Adaptive Anti-Myeloma Immunity 15 PROJECT 3: Adoptive Immunotherapy for Multiple Myeloma Using Educated T Cells 23 CORE A: Administrative and Clinical Support 31 CORE B: ..
  52. CLONAL GVL/GVH REACTIONS AND ADOPTIVE IMMUNOTHERAPY
    ROBERT TRUITT; Fiscal Year: 1990
    ..The proposed studies are a systematic approach to optimizing the GVL effect while minimizing the GVH effect of cloned CTL. In addition, they will enable us to gain significant new insights into the pathogenesis of clonal GVH reactions...
  53. Mixed Chimerism as a Model for Adoptive Immunotherapy
    George Georges; Fiscal Year: 2004
    ..We propose to study adoptive immunotherapy strategies experimentally using dogs with stable mixed donor/host hematopoietic chimerism as a model for ..
  54. Novel Cellular Therapies for Ph+ leukemia
    RICHARD A contact VAN ETTEN; Fiscal Year: 2010
    ..well- characterized mouse model of CML and Ph+ B-ALL to determine the efficacy and cellular mechanisms of adoptive immunotherapy with allogeneic T-lymphocytes or natural killer (NK) cells...
  55. Novel Cellular Therapies for Ph+ leukemia
    RICHARD VAN ETTEN; Fiscal Year: 2009
    ..well- characterized mouse model of CML and Ph+ B-ALL to determine the efficacy and cellular mechanisms of adoptive immunotherapy with allogeneic T-lymphocytes or natural killer (NK) cells...
  56. MECHANISMS OF SUCCESSFUL ADOPTIVE IMMUNOTHERAPY
    ROBERT TRUITT; Fiscal Year: 1980
    An experimental treatment model using allogeneic bone marrow transplantation (i.e., adoptive immunotherapy) in combination with chemoradiotherapy for the treatment of a spontaneous leukemia in mice has been developed...
  57. Strategies to Enhance Adoptive Transfer T Cell Clones
    Stanley Riddell; Fiscal Year: 2007
    ..augment an immune response in vivo and provide therapeutic benefit, and there is increasing evidence that adoptive immunotherapy with T cells has therapeutic activity in human malignancies and infection...
  58. Strategies to Enhance Adoptive Transfer T Cell Clones
    Stanley Riddell; Fiscal Year: 2006
    ..augment an immune response in vivo and provide therapeutic benefit, and there is increasing evidence that adoptive immunotherapy with T cells has therapeutic activity in human malignancies and infection...
  59. Strategies to Enhance Adoptive Transfer T Cell Clones
    Stanley Riddell; Fiscal Year: 2005
    ..augment an immune response in vivo and provide therapeutic benefit, and there is increasing evidence that adoptive immunotherapy with T cells has therapeutic activity in human malignancies and infection...
  60. Strategies to Enhance Adoptive Transfer T Cell Clones
    Stanley Riddell; Fiscal Year: 2009
    ..augment an immune response in vivo and provide therapeutic benefit, and there is increasing evidence that adoptive immunotherapy with T cells has therapeutic activity in human malignancies and infection...
  61. Optimized ex vivo expansion of anti-tumor Th1 and Tc1 for adoptive immunotherapy.
    MARY DISIS; Fiscal Year: 2009
    ..We therefore believe that this 2 year proposal is consonant with Recovery Act goals by promoting job creation, economic development, and accelerating the pace and achievement of scientific research. ..
  62. Optimized ex vivo expansion of anti-tumor Th1 and Tc1 for adoptive immunotherapy.
    MARY L contact DISIS; Fiscal Year: 2010
    ..We therefore believe that this 2 year proposal is consonant with Recovery Act goals by promoting job creation, economic development, and accelerating the pace and achievement of scientific research. ..
  63. LIPOPEPTIDE VACCINE TO PREVENT HCMV INFECTION AFTER BMT
    Don Diamond; Fiscal Year: 2000
    ..An adoptive immunotherapy strategy using CTL has proved successful but is impractical for general use in BMT centers...
  64. LIPOPEPTIDE VACCINE TO PREVENT HCMV INFECTION AFTER BMT
    Don Diamond; Fiscal Year: 2001
    ..An adoptive immunotherapy strategy using CTL has proved successful but is impractical for general use in BMT centers...
  65. LIPOPEPTIDE VACCINE TO PREVENT HCMV INFECTION AFTER BMT
    Don Diamond; Fiscal Year: 2002
    ..An adoptive immunotherapy strategy using CTL has proved successful but is impractical for general use in BMT centers...
  66. LIPOPEPTIDE VACCINE TO PREVENT HCMV INFECTION AFTER BMT
    Don Diamond; Fiscal Year: 1999
    ..An adoptive immunotherapy strategy using CTL has proved successful but is impractical for general use in BMT centers...
  67. TUMOR SPECIFIC TIL FROM RENAL CANCER
    Arie Belldegrun; Fiscal Year: 1990
    ..lymphocytes (TIL) obtained from freshly resected surgical specimens is an experimental approach to adoptive immunotherapy of cancer...
  68. Universal MUC1 Targeted Immunotherapy
    Rimas Orentas; Fiscal Year: 2009
    ..in transduced immune cells, and the target itself are unique with respect to the standard means by which adoptive immunotherapy is proposed for treating cancer. The MUC1-specific TCR identified by Dr...
  69. CHRONIC LYMPHOCYTIC LEUKEMIA RESEARCH CONSORTIUM
    Thomas Kipps; Fiscal Year: 1999
    ..Project 4 (Gribben PI) examines the potential for autologous or allogeneic adoptive immunotherapy of CLL...
  70. EVALUATION OF ADOPTIVE T CELL THERAPY FOR HIV
    DEBORAH LEWINSOHN; Fiscal Year: 1999
    ..In conjunction with others in the laboratory, I have evaluated adoptive immunotherapy of HIV infection with in vitro expanded, autologous, gene-modified HIV- specific CD8+ CTL clones to ..
  71. Neuroimmunology of Vaccines in Adoptive T-cell Therapy for Brain Tumor
    John H Sampson; Fiscal Year: 2010
    ..While high-dose IL-2 has been utilized in most human clinical trials of adoptive immunotherapy for maintenance and expansion of transferred lymphocytes, recent studies in murine models have ..
  72. EVALUATION OF ADOPTIVE T CELL THERAPY FOR HIV
    DEBORAH LEWINSOHN; Fiscal Year: 2000
    ..In conjunction with others in the laboratory, I have evaluated adoptive immunotherapy of HIV infection with in vitro expanded, autologous, gene-modified HIV- specific CD8+ CTL clones to ..
  73. EVALUATION OF ADOPTIVE T CELL THERAPY FOR HIV
    DEBORAH LEWINSOHN; Fiscal Year: 2001
    ..In conjunction with others in the laboratory, I have evaluated adoptive immunotherapy of HIV infection with in vitro expanded, autologous, gene-modified HIV- specific CD8+ CTL clones to ..
  74. EVALUATION OF ADOPTIVE T CELL THERAPY FOR HIV
    DEBORAH LEWINSOHN; Fiscal Year: 2002
    ..In conjunction with others in the laboratory, I have evaluated adoptive immunotherapy of HIV infection with in vitro expanded, autologous, gene-modified HIV- specific CD8+ CTL clones to ..
  75. TCR Transduction for EBV Specific Immunotherapy
    Rimas Orentas; Fiscal Year: 2001
    TCR TRANSDUCTION FOR EBV-SPECIFIC IMMUNOTHERAPY. Adoptive immunotherapy with polyclonal cytotoxic T cell lines (CTL) has met with clinical success in the treatment of post-transplant lymphoma, an Epstein-Barr virus (EBV)-associated ..
  76. TCR Transduction for EBV Specific Immunotherapy
    Rimas Orentas; Fiscal Year: 2002
    TCR TRANSDUCTION FOR EBV-SPECIFIC IMMUNOTHERAPY. Adoptive immunotherapy with polyclonal cytotoxic T cell lines (CTL) has met with clinical success in the treatment of post-transplant lymphoma, an Epstein-Barr virus (EBV)-associated ..
  77. TCR Transduction for EBV Specific Immunotherapy
    Rimas Orentas; Fiscal Year: 2003
    TCR TRANSDUCTION FOR EBV-SPECIFIC IMMUNOTHERAPY. Adoptive immunotherapy with polyclonal cytotoxic T cell lines (CTL) has met with clinical success in the treatment of post-transplant lymphoma, an Epstein-Barr virus (EBV)-associated ..
  78. Lentiviral Vectors for TCR Immunotherapy Targeted to melanoma
    Boro Dropulic; Fiscal Year: 2006
    ..Lentigen's collaborator Dr. Michael Nishimura has helped pioneer adoptive immunotherapy as a potential therapeutic approach for melanoma...